In breast cancer (BC), a variety of studies have investigated the clinical value of tumor-infiltrating leukocytes [CD45+ cells that are >90% lymphocytes] (4) and immune gene signature expression (5–8) with significant findings obtained for HER2-positive (HER2+) and triple negative (TN) BC. Here, PTPRC is linked to breast cancer.